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OBJECTIVE — Subclinical inﬂammation is an important risk factor for type 2 diabetes and
diabetes complications. However, data on the association between inﬂammation and acute
diabetic foot syndrome are scarce. The aim of this study was to compare systemic immune
mediators in diabetic patients with and without an ulcer and to identify modulating factors.
RESEARCH DESIGN AND METHODS — Circulating levels of acute-phase proteins,
cytokines, and chemokines were measured in diabetic patients with an ulcer (n  170) and
without an ulcer (n  140). Of the patients, 88% had type 2 diabetes.
RESULTS — Patients with an acute foot ulcer had higher levels of C-reactive protein (CRP),
ﬁbrinogen, interleukin (IL)-6, macrophage migration inhibitory factor, macrophage inﬂamma-
tory protein-1, and interferon-–inducible protein-10 as well as lower levels of RANTES
(regulated on activation normal T-cell expressed and secreted) (all P  0.01). No differences
were found for IL-8, IL-18, and monocyte chemoattractant protein-1. Most of these associations
persisted after adjustment for demographic and anthropometric data, metabolic confounders,
and diabetes complications. In multivariate models, size of ulcer according to the University of
Texas classiﬁcation but not the grade of infection was independently associated with three
markers of subclinical inﬂammation (CRP, IL-6, and ﬁbrinogen).
CONCLUSIONS — We demonstrate in our cross-sectional study that acute foot ulcers and
their severity are associated with a marked upregulation of acute-phase proteins, cytokines, and
chemokines independently of the concomitant infection. Further studies should investigate
whetheranactivationoftheimmunesystemprecedesthedevelopmentoffootulcerandwhether
anti-inﬂammatory therapies might be effective.
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B
ecause the worldwide incidence of
diabetes is increasing rapidly (1),
the diabetic foot syndrome becomes
more and more important as a major dia-
betes complication. The lifetime risk of a
diabetic patient for development of a
chronicfootwoundhasbeenestimatedto
reach 15–25% (2), and, despite consider-
able international efforts, foot ulcers con-
tinue to be responsible for a high number
of lower-limb amputations that are asso-
ciated with a substantial decrease in qual-
ity of life and increased risk of mortality
(3).
The major risk factors for foot ulcer
are diabetic polyneuropathy and periph-
eralarterialdisease(4).Interestingly,data
ontherelevanceofsystemicinﬂammation
are very scarce in this context, although
low-grade immune activation represents
an important risk factor not only for the
development of type 2 diabetes (5) but
also for several macrovascular (myocar-
dial infarction and stroke) and microvas-
cular complications (neuropathy and
nephropathy) (6–8). The status of the
immunesystemmayberelevantatseveral
stages in the development of chronic
wounds. Immune activation may precede
theincidenceofadiabeticfootulcerinthe
same way that it precedes the manifesta-
tion of type 2 diabetes and coronary heart
disease (5,6). Because pro- and anti-
inﬂammatory processes are crucial in the
different phases of wound healing, it is
conceivable that disturbances of the im-
mune system interfere with tissue ho-
meostasis and wound healing after the
manifestation of ulcers and lead to the
chronic, nonhealing wounds that are
characteristic of diabetic foot syndrome.
Given the surprising paucity of data
on the role of systemic inﬂammation in
diabetic foot ulcers, we evaluated the as-
sociation between foot ulcers and im-
mune status in a cross-sectional study in
diabetic patients with and without foot
ulcers by measuring a range of immune
mediators (acute-phase proteins, cyto-
kines, and chemokines) representing dif-
ferent aspects of the immune system. The
mainaimsofthestudywere1)tocompare
circulating levels of these immune medi-
atorsbetweenbothgroups,2)tousemul-
tivariate regression models to identify
potential confounders of these associa-
tions, and 3) to investigate whether sys-
temic immune activation was associated
with the severity of the foot ulcer.
RESEARCH DESIGN AND
METHODS— Between August 2003
and November 2005, we recruited 282
consecutive diabetic patients with an
acute foot ulcer who were hospitalized at
the German Diabetes Clinic and 175 dia-
betic patients without a history of foot ul-
cer who were admitted to our outpatient
unit. Fasting blood samples were drawn
on the ﬁrst day after admission for the
patients with an ulcer and on the day of
their medical examination in the outpa-
tient unit for the patients without an ul-
cer. Plasma and serum samples were
stored at 80°C until analysis. The study
was approved by the Ethics Committee of
Heinrich Heine University Du ¨sseldorf.
Written informed consent was obtained
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was performed according to the Declara-
tion of Helsinki.
Of all patients recruited, those with
missingessentialclinicaldata,currentim-
munomodulating treatment (e.g., ste-
roids, azathioprine, or ciclosporin), a
history of neoplastic disease, surgical or
angioplastic intervention before the
study, or acute respiratory or genitouri-
nary infections and subjects who had
been recruited more than once (only the
ﬁrstobtainedbiosampleswereused)were
excluded (supplementary Figs. A1 and A2,
available in an online appendix at http://
care.diabetesjournals.org/cgi/content/full/
dc08-2318/DC1). Thus, the following
analyses are based on 170 patients with
and 140 patients without a foot ulcer.
Demographic, anthropometric, and
metabolic data as well as information on
comorbiditiesanddiabetescomplications
were extracted from the patients’ medical
records. Levels of total cholesterol, HDL
cholesterol, LDL cholesterol, triglycer-
ides, and A1C were determined using
standard laboratory methods. The classi-
ﬁcation of diabetes was based on the
guidelines of the German Diabetes Asso-
ciation (9). Diabetic neuropathy was de-
ﬁned as the presence of symptomatic or
asymptomatic neuropathy using the neu-
ropathy symptom score and the neurop-
athy deﬁcit score, respectively. Peripheral
arterial disease (PAD) was staged accord-
ing to Fontaine with reduction of walking
distance of 200 m as the minimal crite-
rion for clinically relevant PAD (Fontaine
stage IIb) (10).
The diagnosis of retinopathy was
based on one-ﬁeld funduscopy; diabetic
nephropathy was deﬁned as urinary ex-
cretion of albumin 200 g/min at two
different time points, macroalbuminuria,
or renal failure. The size and depth of the
foot ulcer was graded according to the
University of Texas classiﬁcation with
stratiﬁcation into grades 0–3 as reported
elsewhere (11). The grade of wound in-
fection was subclassiﬁed into four differ-
ent categories: 1, no sign of infection; 2,
slight redness; 3, explicit redness and/or
erysipelas; and 4, purulent or nonpuru-
lent phlegmon. Hypertension was de-
ﬁned as systolic/diastolic blood pressure
140/90 mmHg or use of any antihyper-
tensive medication. Hyperlipidemia was
deﬁned as total cholesterol 200 mg/dl,
LDL cholesterol 120 mg/dl, triglycer-
ides 150 mg/dl, or use of any lipid-
lowering medication.
Immunological measurements
C-reactive protein (CRP) and ﬁbrinogen
were measured in plasma samples with a
high-sensitivity latex-enhanced nephelo-
metric assay on a BN II analyzer (Dade
Behring, Marburg, Germany) using
immmunonephelometry, respectively
(12). Serum levels of the cytokines inter-
leukin (IL)-6, macrophage migration in-
hibitory factor (MIF), and regulated on
activation, normal T-cell expressed and
secreted (RANTES) were determined us-
ing ELISAs (for IL-6 from Sanquin [Am-
sterdam, the Netherlands] and for MIF
and RANTES from R&D Systems [Wies-
baden, Germany]) as described previ-
ously (12–14). Serum levels of IL-8, IL-
18, monocyte chemoattractant protein-1
(MCP-1), macrophage inﬂammatory pro-
tein-1 (MIP-1), and interferon-–
inducible protein-10 (IP-10) were
quantiﬁed using a bead-based multiplex
assay on a Luminex 100 analyzer (Lumi-
nex, Austin, TX) as described earlier (15).
The intra- and interassay coefﬁcients of
variation of quality control test sera were
10 and 20%, respectively.
Statistical analyses
Data are given as proportions (percent-
age) for categorical variables, as means 
SD for continuous variables with Gauss-
iandistribution,andasmedian(25thper-
centile; 75th percentile) for continuous
variables with non-Gaussian distribution.
Categorical variables with two or more
than two classes were compared using
Fisher’s exact test and a 	
2 test, respec-
tively. Continuous variables with Gauss-
ian distribution were compared using
Student’s t test. A Mann-Whitney test or
Kruskal-Wallistest(withDunn’smultiple
comparison test as a posttest) was used to
compare continuous variables without
Gaussiandistribution.Univariateassocia-
tions between markers of inﬂammation
were described with Spearman correla-
tioncoefﬁcients(r).Associationsbetween
circulating concentrations of immune
mediators and the presence of a foot ulcer
or indicators of its severity (University of
Texas grade, grade of infection) were an-
alyzed using multiple linear regression
models with concentrations of immune
markers (ln-transformed in case of non-
normality)asdependentvariablesandex-
istence of a foot ulcer and potentially
confounding variables as independent
variables. For all statistical analyses, P 
0.05wasconsideredtobestatisticallysig-
niﬁcant. Analyses were conducted using
SAS (version 9.1; SAS Institute, Cary,
NC).
RESULTS— Patients with and with-
out a foot ulcer were mostly patients with
type 2 diabetes. Those with an ulcer were
older, had lower systolic and diastolic
blood pressure, lower total and HDL cho-
lesterol levels, lower A1C, more frequent
PAD, and other diabetes complications
(i.e., neuropathy, retinopathy, nephropa-
thy, and coronary heart disease) and were
more often treated with insulin (Table 1).
Immune activation in diabetic
patients with a foot ulcer
Inpatientswithafootulcer,medianlevels
of both acute-phase proteins, high-
sensitivity (hs)-CRP and ﬁbrinogen, were
signiﬁcantly elevated (4.9- and 1.4-fold,
respectively) compared with those in pa-
tients without a history of foot ulcer (P 
0.0001). Similarly, median levels of the
cytokines and chemokines IL-6, MIF,
IP-10 (all P  0.0001), and MIP-1 (P 
0.008) were elevated 3.3-, 1.8-, 1.4-, and
1.3-fold, respectively, whereas no sig-
niﬁcant differences were found for IL-
18,IL-8,andMCP-1.Incontrast,serum
levels of RANTES were 1.3-fold lower
(P  0.0001) in patients with an ulcer
compared with those without an ulcer
(Table 2).
To account for imbalances between
both groups, the association of immune
mediators with foot ulcer was assessed in
multiple linear regression models (Table
3). Notably, all associations that were
found in unadjusted comparisons per-
sistedafteradjustmentforage,sex,diabe-
tes type, metabolic factors (BMI, A1C,
hypertension, and hyperlipidemia), and
comorbidities (PAD, neuropathy, and
coronary heart disease) (all P  0.003).
As a sensitivity analysis, all analyses
were repeated after exclusion of patients
with type 1 diabetes, which led to virtu-
ally unaltered results for type 2 diabetes
alone(datanotshown).Inclusionofother
diabetes complications (retinopathy and
nephropathy) did not change the ob-
served associations (data not shown).
The analysis of correlations between
immune mediators revealed stronger as-
sociations in patients with a foot ulcer
compared with those without a history of
foot ulcer (supplementary Table A1,
available in an online appendix). Almost
all correlations were positive, and the
strongest correlations were found be-
tween IL-6, CRP, and ﬁbrinogen (Spear-
man’s r 0.59–0.78 in patients with an
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an ulcer; all P  0.0001), whereas corre-
lations between IL-6, MIF, IL-18, IL-8,
MCP-1,MIP-1,andIP-10werelesspro-
nounced or absent.
Association of proinﬂammatory
mediators with severity of foot ulcer
Foot ulcer comprised all University of
Texas grades (0, 1.8%; 1, 18.8%; 2,
35.9%; and 3, 43.5%) and all four grades
ofinfection(1,7.1%;2,14.1%;3,27.1%;
and 4, 51.8%). The frequency of osteo-
myelitis differed signiﬁcantly between
University of Texas grades (1, 6%; 2,
18%; and 3, 45%; P  0.001). In unad-
justed analyses, patients with foot
wounds of University of Texas grade 3
had signiﬁcantly higher levels of hs-CRP,
ﬁbrinogen, and IL-6 compared with pa-
tients with foot wounds of University of
Texas grade 1, whereas no differences
were found for the other immune media-
tors (Table 4). Again, these associations
persisted after adjustment for age, sex, di-
abetes type, metabolic factors (BMI, A1C,
hypertension, and hyperlipidemia), co-
morbidities (PAD, neuropathy, and coro-
naryheartdisease),andgradeofinfection
(CRP P  0.010; ﬁbrinogen P  0.004;
IL-6 P  0.003) (supplementary Table
A2, available in an online appendix). Ad-
ditionaladjustmentforthepresenceofos-
teomyelitis virtually did not alter the
results (data not shown). When the asso-
ciation between systemic inﬂammation
and grade of infection was analyzed, pa-
tients with an ulcer and infection grade 4
had signiﬁcantly higher circulating con-
centrations of hs-CRP and IL-6 than pa-
tients with infection grades 1 and/or 2
(supplementaryFigureA3,availableinan
online appendix), whereas no differences
between grades of infection were found
for the other immune mediators (data not
shown). However, these associations dis-
appeared after adjustment for University
of Texas grade of ulcer and metabolic co-
variables (P  0.1) (supplementary Table
A3, available in an online appendix), so
that University of Texas grade but not
gradeofinfectionwasanindependentde-
terminant of markers of systemic inﬂam-
mation in patients with a foot ulcer.
CONCLUSIONS — Our study has
three major ﬁndings. 1) Diabetic patients
with foot ulceration showed an upregula-
tion of circulating levels of a range of
acute-phase proteins, cytokines, and che-
mokines and lower levels of the chemo-
kine RANTES compared with diabetic
patients without a history of foot ulcer. 2)
These associations persisted when age,
sex, diabetes type, metabolic factors, and
comorbidities were taken into account in
multiple regression models. 3) Severity of
foot ulcer based on the University of
Texas classiﬁcation was associated with
levels of CRP, IL-6, and ﬁbrinogen in
unadjusted comparisons and in multiple
linear regression models.
Theﬁndingofanalteredimmunesta-
tus in patients with foot ulceration is in-
teresting in several ways. First, only some
markers of inﬂammation were upregu-
lated (CRP, ﬁbrinogen, IL-6, MIF, MIP-
1, and IP-10) and others were not (IL-8,
IL-18, and MCP-1), whereas RANTES
levels were even downregulated. These
resultsindicateaspeciﬁcandnonrandom
alterationoftheimmunestatusinpatients
Table 1—Characteristics of the study population
n
Patients with
ulcer
Patients without
ulcer P
n 310 170 140 —
Type 1/type 2 diabetes (n) 310 13/157 23/117 0.02
Age (years) 310 67 (59; 75) 62 (52; 69) 0.0001
Sex (male/female) 310 100/70 76/64 NS
BMI (kg/m
2) 294 29.3  6.6 29.9  5.4 NS
Systolic blood pressure (mmHg) 264 134  19 142  22 0.003
Diastolic blood pressure (mmHg) 264 73  10 78  10 0.0005
Hypertension (%) 308 91 75 0.0001
Cholesterol (mmol/l) 289 4.86  1.29 5.38  1.09 0.0007
HDL cholesterol (mmol/l) 278 1.19  0.39 1.29  0.41 0.024
LDL cholesterol (mmol/l) 278 2.95  1.09 3.18  0.93 NS
Triglycerides (mmol/l) 290 1.67 (1.19; 2.17) 1.79 (1.09; 2.56) NS
Hyperlipidemia (%) 305 78 80 NS
A1C (%) 301 7.64  1.58 8.27  1.58 0.0006
History of diabetes complications
Neuropathy (%) 307 88 54 0.0001
PAD (%) 307 66 9 0.0001
Retinopathy (%) 308 74 16 0.0001
Nephropathy (%) 305 67 33 0.0001
Coronary heart disease (%) 306 39 19 0.0001
Diabetes therapy 303 0.0001
Diet only (%) 5 9
OAD (%) 20 48
OAD 
 insulin (%) 8 4
Insulin (%) 67 39
Data are absolute numbers, proportions, means  SD, or medians (25th percentile; 75th percentile). OAD,
oral antidiabetes drug.
Table2—Systemicimmunemediatorconcentrationsinpatientswithandwithoutdiabeticfoot
ulcer
Immune
mediator Patients with ulcer
Patients without
ulcer P
CRP (mg/l) 11.7 (3.3; 38.2) 2.4 (1.0; 5.0) 0.0001
Fibrinogen (g/l) 5.5  1.6 3.8  0.9 0.0001
IL-6 (pg/ml) 12.4 (6.9; 30.3) 3.8 (2.2; 5.2) 0.0001
MIF (ng/ml) 7.7 (5.6; 11.9) 4.3 (3.1; 6.6) 0.0001
IL-18 (pg/ml) 118.3 (84.2; 179.0) 122.7 (85.0; 172.0) NS
IL-8 (pg/ml) 11.4 (7.1; 18.3) 10.0 (6.8; 15.9) NS
MIP-1 (pg/ml) 82.6 (54.6; 132.7) 61.2 (44.1; 107.4) 0.008
MCP-1 (pg/ml) 291.0 (202.2; 381.9) 303.3 (213.8; 415.6) NS
IP-10 (pg/ml) 419.8 (309.9; 543.4) 299.4 (216.9; 401.6) 0.0001
RANTES (ng/ml) 76.9  38.2 100.3  44.7 0.0001
Data are means  SD or medians (25th percentile; 75th percentile).
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mune activation.
A parallel upregulation of IL-6, CRP,
and ﬁbrinogen is biologically plausible
because IL-6 is known to increase the re-
lease of both acute-phase proteins, which
is reﬂected in the high correlations be-
tween the systemic levels of these mark-
ers. Increased concentrations of CRP and
ﬁbrinogen in diabetic patients with foot
ulcers compared with age- and sex-
matcheddiabeticpatientswithoutfootul-
cers have been described previously (16),
butthisstudydidnotcontrolforpotential
confounders and severity of ulceration.
We also included several chemokines
(IL-8, MCP-1, MIP-1, IP-10, RANTES,
andMIF),whichareknownascrucialme-
diators in wound healing. The levels of
most chemokines in our study were not
correlated with levels of IL-6, CRP, and
ﬁbrinogen, therefore representing a dif-
ferent compartment of the immune sys-
tem. Thus, their measurement is not
redundant and yields important addi-
tional information beyond that for tradi-
tional markers of inﬂammation.
Chemokines recruit leukocytes to sites of
injury and orchestrate the migration of
other cells such as keratinocytes, endo-
thelial cells, and ﬁbroblasts during the
different stages of wound healing. No-
tably, this process is disturbed in pa-
tientswithdiabetes,andaroleofaltered
chemokine expression in this context
has been postulated (17). Although the
local presence of MCP-1, MIP-1, and
RANTES seems to be crucial for the nor-
mal healing of the wound in mice and
humans, elevated levels of MIF and IP-10
impairedthisprocess(18–21).Ourstudy
demonstrates that patients with foot ulcer
display elevated systemic levels of MIP-
1, MIF, and IP-10, decreased RANTES
levels, and unchanged concentrations of
MCP-1 and IL-8. Although the putative
local expression of chemokines does not
necessarily translate into systemic con-
centrations,ourresultsmayreﬂectacom-
bination of normal and abnormal wound
repairmechanisms,combinedwithanac-
tivationoftheacute-phasereactionbythe
acute wound.
Although the association between an
acute-phase response and diabetic foot
ulcer has been described before (16), our
study considerably extends previous
work.First,itcomprisesacomprehensive
measurement of multiple immune medi-
ators regulated independently from each
other. Second, it takes into account the
effect of confounding factors on the asso-
ciation between systemic inﬂammation
and foot ulcer to ensure that the associ-
ations reported here are not affected
by age, sex, obesity, metabolic markers,
and other comorbidities. Finally, we de-
scribe an association between IL-6, CRP,
and ﬁbrinogen with the severity of the ul-
ceration and grades of infection. Impor-
tantly, the association with University of
Texas grades persisted after adjustment
for multiple confounders including infec-
tion, whereas the association with grades
ofinfectionwasabolishedbyadjustingfor
University of Texas grades and metabolic
confounders.Anassociationofﬁbrinogen
and CRP with severity and infection of
foot ulcers has recently been described
(22,23).However,ourdatarevealthatthe
elevated levels of markers of an acute-
phaseresponsearemainlyassociatedwith
the severity of ulceration, whereas the
Table 3—Association between immune mediators and acute foot ulcer: multivariable regression models
Immune
mediator
Model 1 Model 2 Model 3a Model 3b Model 4
 P  P  P  P  P
CRP (mg/l) 1.59 0.0001 1.59 0.0001 1.66 0.0001 1.70 0.0001 1.74 0.0001
Fibrinogen (g/l) 0.34 0.0001 0.33 0.0001 0.35 0.0001 0.32 0.0001 0.35 0.0001
IL-6 (pg/ml) 1.58 0.0001 1.50 0.0001 1.48 0.0001 1.51 0.0001 1.47 0.0001
MIF (ng/ml) 0.70 0.0001 0.69 0.0001 0.70 0.0001 0.76 0.0001 0.75 0.0001
IL-18 (pg/ml) 0.13 0.17 0.14 0.16 0.15 0.15 0.20 0.075 0.22 0.077
IL-8 (pg/ml) 0.08 0.45 0.00 1.00 0.01 0.94 0.05 0.70 0.04 0.79
MIP-1 (pg/ml) 0.17 0.072 0.22 0.023 0.23 0.028 0.33 0.0027 0.35 0.0029
MCP-1 (pg/ml) 0.06 0.49 0.03 0.74 0.03 0.73 0.10 0.31 0.06 0.53
IP-10 (pg/ml) 0.61 0.0001 0.53 0.0001 0.57 0.0001 0.49 0.0001 0.51 0.0001
RANTES (ng/ml) 0.31 0.0001 0.31 0.0001 0.29 0.0001 0.28 0.0001 0.28 0.0004
Data are regression coefﬁcients () and P values from linear regression analyses. Concentrations of immune markers were ln-transformed in case of nonnormality
(i.e., all except ﬁbrinogen and RANTES). Model 1: adjusted for diabetes type; model 2: model 1 
 adjustment for age and sex; model 3a: model 2 
 adjustment for
BMI, A1C, hypertension, and hyperlipidemia; model 3b: model 2 
 adjustment for PAD, neuropathy, and coronary heart disease; and model 4: full model
(adjustment for all covariables from models 1, 2, 3a, and 3b).
Table 4—Systemic immune mediator levels stratiﬁed by ulcer grade (University of Texas
classiﬁcation)
Immune
mediator UT grade 1 UT grade 2 UT grade 3
n 32 61 74
hs-CRP (mg/l) 5.2 (2.3; 19.4) 11.1 (3.7; 30.7) 21.0 (7.9; 61.6)*
Fibrinogen (g/l) 4.8  1.3 5.3  1.7 6.0  1.6*
IL-6 (pg/ml) 7.9 (3.4; 19.1) 10.5 (6.9; 25.6) 19.8 (8.9; 48.6)†
MIF (ng/ml) 7.9 (5.8; 10.9) 7.0 (5.3; 9.9) 8.6 (6.4; 13.4)
IL-18 (pg/ml) 131.3 (79.9; 193.8) 122.2 (90.7; 169.5) 111.3 (85.8; 188.5)
IL-8 (pg/ml) 9.4 (6.7; 20.2) 11.6 (7.6; 18.5) 12.9 (7.0; 18.1)
MIP-1 (pg/ml) 83.5 (50.3; 214.2) 85.1 (56.2; 127.4) 77.6 (54.2; 136.1)
MCP-1 (pg/ml) 256.6 (158.8; 321.3) 348.4 (220.0; 471.6)‡ 284.2 (206.8; 367.9)
IP-10 (pg/ml) 431.6 (320.0; 558.5) 427.2 (344.9; 517.5) 353.2 (275.0; 543.6)
RANTES (ng/ml) 75.3  35.7 77.7  43.6 75.7  34.1
Data are means  SD or medians (25th percentile; 75th percentile). *P  0.01; †P  0.001; ‡P  0.05,
compared with University of Texas (UT) classiﬁcation grade 1.
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teomyelitis had only a minor impact. De-
spite the aforementioned association of
several chemokines with the presence of
an acute ulceration, no association be-
tween the chemokines analyzed and se-
verity of ulceration could be observed.
This ﬁnding again indicates that acute-
phase reactants and chemokines reﬂect
different aspects of the immune status.
Our study has several limitations that
should be mentioned brieﬂy. First, the
study is a cross-sectional study so that
cause and effect in the association be-
tween systemic inﬂammation and foot ul-
cer cannot be investigated. Longitudinal
studies are needed to investigate the im-
pact of inﬂammation on the development
of foot ulcerations and their prognostic
value. Second, our study population re-
ﬂected the high percentage of patients
with type 2 diabetes in our clinic. The
proportion of patients with type 1 diabe-
teswastoosmalltorunseparateanalyses.
Therefore, our results are valid mainly for
patients with type 2 diabetes as indicated
by sensitivity analyses. Whether the ob-
servedresultsarespeciﬁcfordiabeticfoot
ulcer or represent a common feature of
impaired regeneration of chronic wounds
cannot be inferred from our data as no
nondiabetic control group with chronic
wounds was available, but the scarce data
on systemic immune markers in nondia-
beticchronicwoundsindicatethatatleast
someoftheobservedresultsmaybechar-
acteristicofchroniculcersingeneral(24).
Third, we cannot assess whether systemic
inﬂammation was associated with long-
term response to treatment or reoccur-
rence of ulceration as follow-up data are
not available. Fourth, the two groups of
patientsstudiedwerenotmatchedforpo-
tentialconfounderssuchasage,duration,
and type of diabetes, A1C, smoking hab-
its, and cardiovascular risk factors. Fur-
thermore, we cannot exclude confounding
effects on immune reactions by psychic
stress due to hospital admission and bed
rest in patients with a foot ulcer, although
bedrestseemstoimpairratherthanactivate
immunefunctionviamodulationofcortisol
levels (25).
The strengths of our study include a
relatively large study population, com-
prehensive immunological phenotyping
comprisingdifferentcompartmentsofthe
immune system, and the availability of
additional data on potential confounders
so that multiple regression analyses were
possible to analyze the impact of meta-
bolic factors or comorbidities on immune
activation.
Insummary,ourstudyshowsthatpa-
tients with foot ulcers exhibit a speciﬁc
and nonrandom upregulation of several
acute-phase proteins, cytokines, and che-
mokines and decreased levels of the che-
mokineRANTESinthecirculation.These
associations were independent of multi-
ple potential confounders and were
mainly associated with severity of ulcer-
ation. Further studies are needed to test
whether this immune activation precedes
the development of foot ulcer. Moreover,
the characterization of beneﬁcial and del-
eteriousimmunemediatorsintheprocess
of wound healing in patients with ulcer-
ations would be important to identify
potential therapeutic targets and immu-
nomodulating treatment options.
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